Kornimate/medical-research-clean huggingface dataset:
therapeutic endometrial biopsy

Conditions: Infertility; Endometrium; ART; Endometrial Biopsy

Summary: the aim of this study is to evaluate the potential benefits in implantation, clinical pregnancy and live birth rates by an endometrial biopsy prior to an ivf/icsi treatment. including a follow up on possible pregnancy complications and data on children at birth. further it is planned to aspirate secretions from the uterus and take blood samples during the treatment, which presumably can provide information about the mechanisms underlying the possible effect of the treatment.

randomized controlled prospective clinical study.

Eligibility criteria:
inclusion criteria: * one or more previous failed implantation despite transfer of good quality embryons/blastocyst in a fresh ivf/icsi treatment * planned antagonist treatment * planned standardized hormone treatment * fsh: 2-12 iu/l * age: 18-40 years * bmi: 18-32 * regular menstrual cycles * written consent exclusion criteria: * patients in need for a interpreter * suspected intrauterine abnormalities ( fibromes, polyps, adenomyosis, sactosalpinges) * planned use og assisted hatching or use of specialized media * previous inclusion in the study
infections in hospitalized cirrhotic patients

Conditions: Cirrhosis

Summary: hospitalized cirrhotic patients are at high risk of complications and adverse outcomes. this study aims to determine the current practice and outcomes in these following areas: 1. community-acquired infections 2. nosocomial infections 3. development of second infections 4. factors predicting icu care, organ failure, death, and disability 5. patterns and adequacy of albumin use in infected and non-infected patients 6. per and post-liver transplant outcomes 7. quality-assurance and adequacy of management of complications of cirrhosis such as hepatic encephalopathy, variceal bleeding, hyponatremia, and hypernatremia 8. regional variations in outcomes and therapeutic strategies


Eligibility criteria:
inclusion criteria: * male and female over 18 years of age * cirrhosis as diagnosed by either liver histology or a combination of clinical biochemical (low platelets, elevated bilirubin, and/or inr, low albumin) radiologic (nodular liver on ultrasound) and endoscopic (esophageal varices) criteria * subject must be able to understand and provide informed consent * evaluated in the er or admitted to the hospital for non-elective reasons exclusion criteria: * admitted for elective purpose
evaluating anodal tdcs preceding aphasia therapy

Conditions: Stroke; Aphasia

Summary: the purpose of this study is to determine if non-invasive brain stimulation (transcranial direct current stimulation) delivered prior to language therapy will improve word-finding in individuals with aphasia who are 6 months or greater post-stroke.


Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. first single focal unilateral left hemisphere lesion with diagnosis verified by brain imaging (mri or ct scans) that occurred at least 6 months prior 3. pre-morbidly right handed 4. pre-morbidly fluent english speaker 5. cognitive function sufficient to understand the experiments and follow instructions (per interview with speech pathologist) 6. a baseline aphasia quotient score between 10 to 94 out of 100 points on the western aphasia battery (neither completely without language comprehension/expression nor fully recovered from aphasia). exclusion criteria: 1. ongoing use of cns-active medications 2. ongoing use of psychoactive medications, such as stimulants, antidepressants, and anti-psychotic medications 3. presence of additional potential tdcs risk factors: * damaged skin at the site of stimulation (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.) * presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system * metal in any part of the body, including metal injury to the eye (jewelry must be removed during stimulation) * a history of medication-resistant epilepsy in the family * past history of seizures or unexplained spells of loss of consciousness during the previous 36 months 4. pregnancy in women, as determined by self-report

Keywords: stroke aphasia cva apraxia cerebrovascular accident cerebral stroke speech therapy aphasia therapy non-invasive brain stimulation transcranial direct current stimulation tdcs
scaling mental healthcare in covid-19 with voice biomarkers

Conditions: Major Depressive Disorder; Generalized Anxiety

Summary: this study aims to advance research on group sessions for mental health. the first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and developing workflows for mental health that are both scalable and personalized.

the anticipated impact of this study is defining voice biomarker features and reward functions for a deep reinforcement learning based system from group interactions that improve depression and anxiety outcomes. the investigators' ability to quantify the real-time impact of human-intervention in scaled group video sessions can be very meaningful for creating best practices in the area where measurement is infrequent. the investigators' priority is to scale the optimal mix of individuals for group therapy sessions based on reward functions that maximize improvements in depression and anxiety scores. current group therapy appointments may track little save few who use various group feedback questionnaires (e.g. oq, gcq, or gq). voice biomarkers can play a key role in the real-time measurement of mental health. the proposed work is to conduct a feasibility study on creating reward functions that most effectively enable engagement for group sessions as measured by voice biomarkers before, during, and after group video meetings.

Eligibility criteria:
inclusion criteria: * ownership of a personal iphone (version ios 12.0 or later) and willingness to install and maintain the kintsugi app for remote participation throughout the study duration * able to understand and comply with instructions in english exclusion criteria: * has any other clinically significant medical condition or circumstance that, in the opinion of the investigator, could affect patient safety, preclude evaluation of response, interfere with the ability to comply with study procedures, or prohibit completion of the study * has a visual or physical motor impairment that could interfere with study tasks * is site personnel directly affiliated with this study
a study to assess the effect of venetoclax on ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies

Conditions: Hematologic Malignancies

Summary: a study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.


Eligibility criteria:
inclusion criteria: * participant must have relapsed or refractory non-hodgkin's lymphoma (nhl). * participant must have histologically documented diagnosis of one of the following nhl subtypes: diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), lymphoplasmacytic lymphoma (lpl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), t-cell prolymphocytic lymphoma (t-pll), waldenström's macroglobulinemia (wm) * has an eastern cooperative oncology group (ecog) performance score of less than or equal to two. * must have adequate bone marrow, coagulation, renal and hepatic function as described in the protocol. * a female of non-childbearing potential as described in the protocol. exclusion criteria: * history of currently active, clinically significant cardiovascular disease. * if the participant has had prior stem cell transplantation, it must have been more than 100 days prior to start of study drug, with no graft versus host disease, and no immunosuppression therapy. * evidence of transformation of the lymphoma immediately prior to study entry. * evidence of central nervous system involvement by lymphoma.

Keywords: cancer hematologic malignancies, venetoclax ethinyl estradiol relapsed or refractory non-hodgkin's lymphoma non-hodgkin's lymphoma
safety and effectiveness of adding adefovir dipivoxil and nelfinavir to the anti-hiv therapy of hiv-infected children

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give adefovir (a new anti-hiv drug) plus nelfinavir to hiv-infected children who are already receiving other anti-hiv medications.

during the first phase of the study (days 1-6), the safety and tolerability of multiple doses of adf is assessed when administered simultaneously with the patient's reverse transcriptase inhibitor (rti) regimen. the second phase begins on day 7 when nelfinavir is added to the therapy regimen for an additional 15 weeks. adf pharmacokinetics are measured on days 1, 2, and 7 (on a subset of 18 patients); peak and trough samples are collected on day 28.

Eligibility criteria:
inclusion criteria your child may be eligible for this study if he/she: * is 3 months to 16 years old. * is hiv-positive. * has never taken protease inhibitors or has previously taken ritonavir (rtv), saquinavir (sqv), or indinavir (idv) and is willing to stop the medication at study entry. * is taking an anti-hiv drug combination that will not change during at least the 2 weeks prior to study entry. * agrees to use effective barrier methods of birth control, such as condoms, during the study. * has consent of parent or guardian. exclusion criteria your child will not be eligible for this study if he/she: * has ever taken nfv. * has a history of opportunistic (aids-related) infection. * has any disease or illness that would prevent him/her from completing the study, including cancer. * has taken certain medications, including protease inhibitors at study entry. * is receiving an hiv vaccine at study entry. * is pregnant.

Keywords: dose-response relationship, drug antiviral agents hiv protease inhibitors disease progression rna, viral adenine viral load age factors nelfinavir
the influence of dietary plant sterols and plant stanols on cholesterol and plant sterol levels in atheromatous plaques

Conditions: Atherosclerosis

Summary: this study aims to explore whether the increased supply of dietary plant sterols and plant stanols have any influence on serum levels of phytosterols and on consistency of carotid atheromatous plaques.

this is a double-blind randomized study. the study population will consist of 30 consecutive patients who will undergo an elective carotid endarterectomy due to a tight asymptomatic stenosis. the patients will be randomized into two groups consuming either plant sterol (2g/day) or plant stanol (2g/day) spreads for two to six weeks, until the operation. serum lipids, lipoproteins and sterols will be analyzed at the randomization, before the operation and one month after the operation. the carotid arteries will be examined for their composition of sterols. this study gives new information concerning the relationship between dietary consumption of plant sterols and stanols and the sterol composition of the carotid plaques.

Eligibility criteria:
inclusion criteria: * asymptomatic tight carotid plaques * age 40-80 exclusion criteria: * no

Keywords: cholesterol plant sterols atherosclerotic carotid plaques
effect of high flow nasal cannula versus continues positive airway pressure in adults with obstructive sleep apnea

Conditions: Sleep Apnea

Summary: the participants whom undergo polysomnography study (sleep study) and are found to have mild, moderate or severe obstructive sleep apnea (osa) will have two consecutive titration nights. randomly, they'll do (cpap) titration followed by (hfnc) titration or vice versa. to explore the possibility of the cpap not being superior to hfnc in reduction of sleep apnea events.

the participants undergo three nights in the sleep lab. in their first night they perpetrate polysomnography study (sleep study) and then classifies to have mild, moderate or severe obstructive sleep apnea (osa) or not. those who are diagnosed with osa, will undergo two consecutive titration nights. randomly, they'll do (cpap) titration followed by (hfnc) titration or vice versa. to explore the possibility of the cpap not being superior to hfnc in reduction of sleep apnea events.

Eligibility criteria:
inclusion criteria: * adults patient aging above 18 years * diagnosed with obstructive sleep apnea (osa) based on polysomnography (psg) ranging from mild to severe i.e. more than 5 exclusion criteria: * patients with hypoventilation syndrome * patients with chronic obstructive pulmonary disease * patients who have unstable hemodynamic state, who experienced intolerance to hfnc or cpap * patients who are pregnant * patients recently underwent surgery
parent video feedback intervention study

Conditions: Autism Spectrum Disorder; Parent-Child Relations

Summary: the purpose of this study is to use a randomized controlled trial to test the effectiveness of parent coaching sessions using video-based feedback, compared to the sessions without the use of video-based feedback on parent strategy use.

this study is a randomized controlled trial of video-based feedback interventions for the parents of young children with autism spectrum disorder (asd). in the beginning of the study, each participant will be randomized to the video-based feedback condition (treatment condition) or standard care procedure (control condition). all participants will be asked to implement the strategies taught during the sessions in the home environment (e.g., following the child's lead, sitting face-to-face). participants randomized into the video-based feedback condition (treatment condition) will be asked to video-tape their interactions with their children (maximum 30 mins/week at home during free play, book reading, bath or meal time routines). the therapist then will review the tapes and then use the recorded sessions to give feedback on the parents' use of strategies in addition to providing in-vivo feedback based on the live interactions during the sessions. for parents whose children are randomized into the standard care condition, the families will receive coaching based on in-vivo sessions as described above. for all participants, a battery of assessment (diagnostic, developmental testing), will be administered at the beginning of the study participation, in the mid-point at 3 months, at the end of their 6-month participation of treatment sessions, and then at the follow-up period, 6 months after the end of their participation of the treatment sessions.

Eligibility criteria:
inclusion criteria: * all children who will be enrolled into the early intervention (ei) classroom at the center for autism and the developing brain (cadb) will be invited to participate in the study. exclusion criteria: * we do not have any exclusionary criteria as long as the children meet the inclusion criteria (families with children with asd between 1-4 years who will be enrolling in the cadb early intervention classroom).

Keywords: autism spectrum disorder early intervention parent-mediated intervention
prospective multicentric trial between radiofrequency ablation with vnus closure fast ® and endovenous ablation with 1470 nm diode laser and tulip fiber ® for treatment of primary venous insufficiency.

Conditions: Chronic Venous Insufficiency C2 or Higher

Summary: endovenous ablation of the greater saphenous vein has nowadays the same outcome as open crossectomy and stripping. the two most performed techniques for endovenous ablation are the endovenous laser ablation and the radiofrequency ablation. according to the trial of rasmussen, they are equivalent for occlusion but the lower laser wave lengths resulted in more pain and paresthesia. the newer wave length of 1470 nm showed lesser side effects in observational studies. the aim of this study is to compare radiofrequency ablation with the vnus closure fast ® with laser ablation with a 1470 nm wave length in combination with a new fiber, the tulip fiber ®. this fiber has the shape of a tulip at his tip which avoids point necroses of the vessel wall and on consequence results in lesser side effects from wall perforations such as pain, haematoma,...


Eligibility criteria:
inclusion criteria: * endovenous ablation of the great saphenous vein (gsv) planned * patient signed informed consent * patient must complete the 1 year follow-up * ceap between 2 and 6 * bmi=\<35 * diameter of the gsv in upward position less than 20 mm diameter * no problems in deep venous system exclusion criteria: * no informed consent is signed * latex allergy * arterial insufficiency * deep vein thrombosis or deep vein insufficiency * klippel trenaunay * diameter fo gsv \> 20 mm * cross dilation with 2 or more insufficient side branches * previous gsv operation * redo-operation * carcinoma less than 1 year ago * bmi \> 35 * liver-insufficiency with contraindication for local tumescence * intake of warfarins * pregnancy, breastfeeding, \< 3 months after pregnancy * bilateral gsv insufficiency that has to be treated * cross insufficiency of the accessory saphenous vein or insufficiency of the subterminal valve of the gsv

Keywords: venous insufficiency
application of genomic techniques and image processing using artificial intelligence to obtain a predictor model risk of melanoma

Conditions: Melanoma

Summary: the aim of this study is to develop a predictive model of risk of developing melanoma. the investigators will used artificial intelligence techniques to analysed images patterns obtained by clinical and dermoscopic pictures. the investigators want to defined a new predictive risk model obtained from genetic information and image analysis of pigmented lesions. this model could help to discriminate more accurately those patients who are most likely to develop melanoma in a high-risk population.


Eligibility criteria:
inclusion criteria: * ≥18 years of age; * followed up patients in the pigmented lesions unit at reina sofia university hospital with high risk of developing melanoma (first-degree family/personal history of familiar melanoma and/or melanocyticnevi above 50 and/or dysplastic or atypical nevi); * all nevi for which there is at least one dermatoscopy registry will be included. exclusion criteria: * not enough data in the patient clinical history; * located lesions on the face, scalp, mucous membrane or on acral área; * nodular or metastatic melanoma diagnosis * type v or vi of fitzpatrick phototyping scale
pediatric positive end expiratory pressure (peep) titration using electrical impedence tomography (eit)

Conditions: Pediatric Acute Respiratory Distress Syndrome

Summary: the goal of this clinical trial is to perform a peep titration protocol and use eit to identify the optimal peep at which lung overdistention and collapse are most effectively balanced. the primary and secondary aims of the study are as follows: identify the difference between the optimal peep recommended by eit metrics and the current guideline recommended approach to identifying optimal peep in pards. there will be a statistically significant difference in the recommended optimal peep identified using the eit peep titration tool and that of the peep/fio2 grid recommendations. determine the difference in physiologic metrics between eit optimal peep and the peep/fio2 recommended peep. participants will undergoing eit monitoring while being subjected to peep titration protocol.


Eligibility criteria:
inclusion criteria: * any person who is less than 18 years of age * is on invasive mechanical ventilation * is not spontaneously breathing * meets pards criteria exclusion criteria: * contraindication to the use of eit * hemodynamic instability * contraindications to hypercapnia * patients with uncuffed endotracheal or tracheostomy tubes * diagnosis of pneumothorax or bronchopleural fistula * non-conventional ventilation * any patient on extra-corporeal membrane oxygenation (ecmo) support * less than 1 week post-operatively from cardiac surgery * the following cardiac diagnoses: glenn or fontan physiology, significant right to left shunt * corrected gestational age \< 37 weeks * pregnancy

Keywords: positive end-expiratory pressure electrical impedance tomography respiratory distress
magnesium sulfate in thrombotic thrombocytopenic purpura in intensive care

Conditions: Thrombotic Thrombocytopenic Purpura

Summary: thrombotic thrombocytopenic purpura (ttp) is a potentially life-threatening thrombotic microangiopathy caused by a severe deficiency of adamts13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13). decreased adamts13 activity leads to an accumulation of ultralarge von willebrand factor (vwf) multimers which induce aggregation of platelets and microthrombi. these microthrombi may involve the brain, heart, kidneys and lead to life-threatening organ failures. in experimental models, magnesium sulfate increases cleavage of newly released vwf by adamts13, decreases the endothelial secretion of ultralarge vwf and inhibits the interaction of vwf with platelets. in another thrombotic microangiopathy, magnesium sulfate has been shown to reduce the risk of seizures in women with severe pre-eclampsia. in analogy with its evidence-based therapeutic application in pre-eclampsia and based on a strong rationale for magnesium supplementation in ttp, we propose a phase 3, double blind, placebo controlled, and randomized study to evaluate the efficacy of magnesium sulfate in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis in patients with thrombotic thrombocytopenic purpura.


Eligibility criteria:
inclusion criteria: * age \> or = 18 years * health insurance * signed inform consent by patient or relatives exclusion criteria: * pregnancy * no health insurance

Keywords: thrombotic thrombocytopenic purpura intensive care